{"name":"Clearside Biomedical","slug":"clearside","ticker":"CLSD","exchange":"NASDAQ","domain":"clearsidebio.com","description":"Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.","hq":"Alpharetta, GA","founded":0,"employees":"32","ceo":"George Lasezkay","sector":"Ophthalmology / Drug Delivery","stockPrice":0.41,"stockChange":0,"stockChangePercent":0,"marketCap":"$2M","metrics":{"revenue":18000000,"revenueGrowth":-80.6,"grossMargin":88.1,"rdSpend":18590000,"netIncome":-34352000,"cash":6801000,"dividendYield":0,"peRatio":-0.8,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"XIPERE patent cliff ($0.0B at risk)","drug":"XIPERE","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CLS-AX","genericName":"CLS-AX","slug":"cls-ax","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CLS-AX","genericName":"CLS-AX","slug":"cls-ax","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Clearside Biomedical Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Clearside Biomedical reported its fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $34.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Clearside Biomedical Announces Collaboration with Regeneron Pharmaceuticals","summary":"Clearside Biomedical announced a collaboration with Regeneron Pharmaceuticals to develop and commercialize XIPERE in the United States.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"XIPERE Receives FDA Approval for the Treatment of Non-Infectious Uveitis Affecting the Back of the Eye","summary":"The FDA approved XIPERE for the treatment of non-infectious uveitis affecting the back of the eye.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBDekwtMFpxakFLX19mUlpSWDRtcnVQNk9GbE83QTNxT19RczhzNjhnSkw4alZhMjZQZ3FBeWNreTZHTS1laWJqMURWMlUzRTM3V3hqT3QxSjlmQUxuT0V5Um1ISEdPMmYyU1JHV0Zn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Clearside Biomed (CLSD) - Stock Titan","headline":"If You Invested $1,000 in Clearside Biomed (CLSD)","sentiment":"neutral"},{"date":"2025-12-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5OdWtaYVkxLWpzdXdURVotR3JNWlViT2dqTnpxWG0yYXZBTjZqWVN6U3ZYYmFaQWFsell2c1p4dUlIZXVDYTJpMFBEaVZSWFRnTTNhN1dnaGNneWZf?oc=5","date":"2025-12-14","type":"pipeline","source":"Finimize","summary":"Clearside Biomedical Stumbles Through Bankruptcy And Delisting - Finimize","headline":"Clearside Biomedical Stumbles Through Bankruptcy And Delisting","sentiment":"neutral"},{"date":"2025-12-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOeEN4X0lzQ3NUS3FOQlBsbF9sTjhwUmN0SFpwS3EwZ015RU50VzZLYkowRk1uRmlwS3daMlp5aWtZeTM5QzhKTExueGdiQ09SODF6aldodXNXYlh3cklCUW1FUDlKMlk3Wm1yQ3llWW9lWkRzR3FMdGs3U0tzX01OQ3VZbGlYR1A0MDkyS18xQUZLT0x0cW1ON2xPdllZM2lWZGtmZldCbENVaHJiZzRBVC1zTHptQm1WbE5uX0NDTXZNSk81VUZLbUUwcE96blEtVTk1Mk1zQVltSlRxMnVvQmNMcHRqZmlYUlEzRTJKQkYwNlQ3d1pIS3lUblhuVWs?oc=5","date":"2025-11-24","type":"pipeline","source":"GlobeNewswire","summary":"Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - GlobeNewswire","headline":"Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNcHpLX3pvYVpLZnBRRXBNaERZOE5HU0JJUmlvUThZQ2pScVVaeW51TmxmNDZkQkR2dDZ3QVdFX1JRbUhjRWRJeHhTaG9rc2Q5V3VfU3VRWFROMEdrVGFoSTREV2Y2MlNIT3VZUkV6MU5HWV9wVlpYdHc3SU4xMTYxck1nSXlfZ29ySy1TMXdpZDlTem1RN05QdjBBMWRacXNXRzJ6N3dVc0d4c0ZOZHNKMVE0VUFaVW8tZ2RMY2JOYVJ1TVpDRFlwbw?oc=5","date":"2025-11-24","type":"pipeline","source":"Stocktwits","summary":"CLSD Stock Plummets After Company Files For Bankruptcy Protection - Stocktwits","headline":"CLSD Stock Plummets After Company Files For Bankruptcy Protection","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-17","type":"pipeline","source":"GlobeNewswire","summary":"Clearside Biomedical Announces Plan to Explore Strategic - GlobeNewswire","headline":"Clearside Biomedical Announces Plan to Explore Strategic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNb0FmYmdwX2VtZllUZXNvdUZvQ1B0T0R5VXVibUV6alkxaXhKdjI0b25IQVVldS1ZNFR1cm5WeV83RDRFazQzMFllbkVzSDdwZ01zRXhTTzg4VUpjN0NmcTNMdU1BLWZ3ZWZMYTJJYW53ZnRzWDRJWURnZFdYYlA3SVg2bi1mMWhpWkZTWlpyajd2bG1uT0FRczYxbVI3YTFELUlsNVo4VnRpNWFZcDdNMm0yNld2QjlENzdWY0tKQkZZUnd2R1J2NHdIQkw4SDdPVWNSUVNuTDJMeG54RWVySklteEg4LURKd1dBeE5wRlg3U1UyZ25GbWE5UnZ3QQ?oc=5","date":"2025-05-14","type":"earnings","source":"GlobeNewswire","summary":"Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire","headline":"Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNYjAzN1A2MjVqTTd0WWNKcjc5dTNLWk1tWFQ3Y2diOTZsM2RQaV9fZnF4UjNremdqNnlUSGFNZEFtSGlnd0hJdjRvUW1LSW5CQlRtLWlHWG4zSlNJaGFsLThGNEpxX0hNTmFmbTRYclo4ODNrWWxMcGF0T1dQcDNCMUxVM3pYbnlJcE0weUdVYzNfc2ZpMVE?oc=5","date":"2025-03-27","type":"earnings","source":"Yahoo Finance","summary":"Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance","headline":"Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPc2VOc0ExejM2cTRiRjlSN2FNbzV3VmdDaFJNTjB2THZJX0VYX0dwLWV1M0Y4Q3JpRzBONGVSVHV0a25nOTJjZGdpelFtbnJubk52cFlibnZqZXR4WlpQeUV0SEFvTW5ib3g2SWlKLUxVMDdMN2FYUGNGTW5NWU1PdGhJRUNmcWMtLUpFZ3lJU1IwYkZMMnY3cFJkcWlsMy1OZ29mVWNaYWFWSHFLZmFnNmllRjFma2dJR2R0N2RRSDhtQQ?oc=5","date":"2024-11-06","type":"pipeline","source":"VisionMonday.com","summary":"Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - VisionMonday.com","headline":"Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5rVFlvd29WaGE0ZVphU1Q1ajFmbmlIaGV5WWQ0VWtTU2dlWUFTVXZKRXEybFlBV1JmdjRnSjVheWxpUnFBM0hNaGNXVl9VZlNwR1B0cjM2SF9nVmxLa05lWkJScEl6UQ?oc=5","date":"2024-05-11","type":"pipeline","source":"MarketBeat","summary":"Clearside Biomedical (CLSD) Stock Forecast and Price Target 2026 $CLSD - MarketBeat","headline":"Clearside Biomedical (CLSD) Stock Forecast and Price Target 2026 $CLSD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOSDVXMlJ2NzgwZmpwV1pTcWpVM2RvUzlnaEJZdzkwQUdYbmZJZDB4TTRiNFJwYU1rOTlpbVYwU0ZuQ2t0cTM1Vl8tVGVJRUF1bVlvSGdMMXp1ZnFycjZXWU5xVk5HLUNVZmtSNnRVb0M4RzJjR1hiVkJrVFdob3Z4SnhOMmIzMS03X250STVUYjZRYmNLYWxTcER4Y3o?oc=5","date":"2024-02-25","type":"trial","source":"InvestorPlace","summary":"7 Biotech Penny Stocks on the Verge of Clinical Trial Victory - InvestorPlace","headline":"7 Biotech Penny Stocks on the Verge of Clinical Trial Victory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBHZDlXTVdQdVIwalp6QVo5TW1BSVI5X21NblJJZDJBUEtuZkYyOEJlUjFWZkRxdVF1TDJOcU1tZWRxMjVIVUFrQnVQVmpKY05PS3o2X2JjSHd4M3lBM2hr?oc=5","date":"2019-11-08","type":"pipeline","source":"ChartMill","summary":"CLSD Stock Price, Quote & Chart | CLEARSIDE BIOMEDICAL INC (NASDAQ:CLSD) - ChartMill","headline":"CLSD Stock Price, Quote & Chart | CLEARSIDE BIOMEDICAL INC (NASDAQ:CLSD)","sentiment":"neutral"}],"patents":[{"drugName":"XIPERE","drugSlug":"dexamethasone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Regeneron Pharmaceuticals","Novartis"],"therapeuticFocus":["Ophthalmology"],"financials":{"source":"sec_edgar+yahoo","revenue":1664000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":1664000,"period":"2024-12-31"},{"value":8226000,"period":"2023-12-31"},{"value":8226000,"period":"2023-12-31"},{"value":1327000,"period":"2022-12-31"},{"value":1327000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":18590000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-34352000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":25126000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":32,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.41,"previousClose":0.41,"fiftyTwoWeekHigh":17.1,"fiftyTwoWeekLow":0.31,"fiftyTwoWeekRange":"0.31 - 17.099998","fiftyDayAverage":2.87,"twoHundredDayAverage":8.22,"beta":1.79,"enterpriseValue":57063136,"forwardPE":-0.8,"priceToBook":-0.04,"priceToSales":0.64,"enterpriseToRevenue":17.14,"enterpriseToEbitda":-2.52,"pegRatio":0,"ebitda":-22630000,"ebitdaMargin":0,"freeCashflow":-20525250,"operatingCashflow":-21293000,"totalDebt":61613000,"debtToEquity":0,"currentRatio":2.98,"returnOnAssets":-70.3,"returnOnEquity":0,"analystRating":"3.0 - Hold","recommendationKey":"hold","numberOfAnalysts":2,"targetMeanPrice":60,"targetHighPrice":90,"targetLowPrice":30,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":12.9,"institutionHeldPercent":13.7,"sharesOutstanding":5233981,"floatShares":4540897,"sharesShort":141010,"shortRatio":3.86,"shortPercentOfFloat":2.7,"epsTrailing":-5.11,"epsForward":-0.5,"revenuePerShare":0.65,"bookValue":-10.31,"officers":[{"age":72,"name":"Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.","title":"Director & Principal Executive Officer"},{"age":60,"name":"Mr. Charles A. Deignan","title":"Principal Financial Officer & Principal Accounting Officer"},{"age":57,"name":"Ms. Jenny R. Kobin","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Rick  McElheny","title":"Senior Vice President of Corporate Development & Alliance Management"},{"age":59,"name":"Mr. Rafael V. Andino","title":"Senior Vice President of Engineering & Manufacturing"}],"industry":"Biotechnology","irWebsite":"","website":"https://clearsidebio.com","phone":"678 270 3631"}}